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1. Introduction 
Bladder cancer can occur at any age. However, it is known to be a disease of the middle-
aged or elderly patient. The incidence is variable in different countries and the risk factors 
includes male sex, increasing age, smoking, occupational exposure to carcinogens, chronic 
inflammation, drugs such as phenacitin and cyclophosphamide, and pelvic radiation. In this 
chapter, we will discuss the different symptoms and signs that the bladder cancer patient 
could present with, keeping in mind that non of these presenting features are unique for 
bladder cancer. 
2. Haematuria 
Haematuria is the presenting symptom in up to 80% of patients with bladder 
cancer(Cummings et al., 1992).  It could be Visible (previously called gross or frank 
haematuria), or Non Visible (previously called Dipstick or Microscopic haematuria). It is 
usually intermittent rather than constant, therefore, if a second urine specimen is free of any 
haematuria after a previous positive sample, investigations are still warranted in a bladder 
cancer age range patient. It may be initial or terminal if the lesion is at the bladder neck or in 
the prostatic urethra. The history of smoking or occupational exposure to certain chemicals 
is relevant. The Renal Association and British Association of Urological Surgeons joint 
consensus statement uses the abbreviations VH and NVH to refer to visible and non visible 
haematuria respectively (Kelly et al., 2009). They also define significant haematuria as the 
one that is visible (VH), Symptomatic non visible (sNVH)ie: associated with lower urinary 
tract symptoms, and persistent asymptomatic (aNVH)ie: without association with any 
urinary tract symptoms. Persistence was defined as 2 out of 3 positive urine samples. 
Microscopic or non visible haematuria (NVH) is defined as more than 3 Red blood cells 
(RBCs) per high-powered field(HPF) on a spun specimen by the American Urological 
Association. However, Campbell-Walsh definition is more than 5 RBCs per HPF for spun 
urine and more than 2 RBCs per HPF for unspun urine. The degree of haematuria does not 
correlate with the stage or the grade of the bladder cancer but cancer pick up rate is 
different. Cancer diagnosis is about 20-25% for the VH and 5-10% for the NVH (Khadra et 
al.,2000; Edwards et al.,2006). Majority of cancers discovered when investigating haematuria 
are bladder ones and the rarity relate to the upper urinary tract. Haematuria is an alarming 
presentation especially when asymptomatic. It requires extensive examination and 
investigations to rule out underlying pathologies and in particular bladder or upper urinary 
tract cancers. The role of purposely designed one-stop haematuria clinic has been developed   
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Fig. 1. Diagram showing the common and uncommon presenting symptoms and signs of 
bladder cancer.  
and some evidence is existent that it could well reduce the time to cancer diagnosis and 
treatment (Katmawi-Sabbagh et al., 2010). Patients will require full history and examination 
including detailed information abouthaematuria, its duration and any associated symptoms. 
Smoking, occupation and exposure to chemicals and drugs should be documented. 
Abdominal, genital, and rectal examinations will be required in men. Vaginal examination is 
also important as vaginal bleeding is sometimes mistaken as haematuria in women. Details 
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of required investigations will be discussed at different chapter of this book. Common 
causes of haematuria are listed below in Table 1: 
 
 Infective Neoplasic Others 
Kidney -Pylonephritis
-Tuberculosis(TB) 
-Renal cell 
carcinoma 
-Transitional cell  
  carcinoma (TCC). 
- Squamous cell  
  carcinoma (SCC).  
 
-Trauma
-Stones. 
-Nephrological: 
IgA nephropathy, 
diabetes, Alport's 
syndrome, interstitial 
nephritis, 
papillary necrosis. 
Ureter -Ureteritis
-Tuberculosis 
-TCC
-Adenocarcinoma. 
-SCC
-Trauma.
-Stones. 
Bladder -Bacterial cystitis.
-TB cystitis. 
-Schistosomiasis
-TCC
-Adenocarcinoma 
-SCC
-Trauma
-Stones 
-Foreign bodies. 
Prostate -Bacterial 
prostatitis 
-Granulomatous 
prostatitis.
-Prostate cancer.
-Benign prostatic 
hypertrophy. 
-Trauma
- Iatrogenic: Post 
biopsy. 
Urethra and penis -Urethritis. -SCC.
-TCC. 
 
-Trauma.
-Stricture. 
-Iatrogenic: 
catheterization.  
Table 1. Common causes of Haematuria based on the anatomical location and the causative 
factors.  
3. Lower urinary tract symptoms  
Frequency, nocturia, urgency, and urge incontinence are symptoms of vesical irritability. 
These could be seen in association with haematuria in bladder cancer patients (with or 
without the presence of dysuria or suprapubic pain). These symptoms were previously 
named as irritative symptoms and they have association with diffuse carcinoma in situ (CIS) 
as well as invasive cancer (Farrow et al., 1977).  
4. Flank pain  
Flank pain can be a symptom of advanced bladder cancer representing ureteric obstruction 
due to invasion of bladder muscular wall or the ureter. Tumours cause hydronephrosis as 
they become invasive (Figure 2). This is usually seen with high grade TCC rather than low 
grade (Table 2).   
Alternatively hydronephrosis with or without pain could happen when there is 
involvement of the ureteric orifice (Leibovitch et al., 1993).  
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1973 World Health Organisation (WHO) grading 
Grade 1: Well differentiated
Grade 2: Moderately differentiated 
Grade 3: Poorly differentiated 
 
2004 WHO grading – Flat lesions:
Hyperplasia (flat lesion without atypia or papillary)
Reactive Atypia (flat lesion with atypia) 
Atypia of unknown significance 
Urothelial dysplasia 
Urothelial Carcinoma in situ (CIS) 
 
2004 WHO grading – Papillary lesions:
Urothelial Papilloma (wich is a completely benign lesion)
Papillary urothelial neoplasm of low malignant potential 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
 
Table 2. WHO grading in 1973 and in 2004 (Sauter el al.,2004) 
 
Fig. 2. An Intravenous urography (I.V.U) of a 76 year old man presented with haematuria 
and left sided loin pain. It shows left sided hydroureteronephrosis and large filling defect in 
the bladder. Cystoscopy confirmed a bladder tumour and histology revealed invasive G3 
pT2 transitional cell carcinoma of the bladder.  
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Pyelonephritis may result if obstruction is complicated with infection.  Flank pain and 
hydronephrosis could also be seen in cases of retroperitoneal metastasis. Flank pain caused 
by a bladder tumour is rarely encountered as the obstruction arises gradually. It should be 
distinguished from the one caused by a urinary stone which could also be associated with a 
degree of haematuria, but the colicky pain caused by a stone is normally of sudden onset 
and of higher intensity than that caused by a gradually occurring obstruction. Another 
differential diagnosis is the flank pain caused by a clot colic related to a bleeding from upper 
urinary tract transitional cell carcinoma or renal cell carcinoma. 
5. Recurrent urinary tract infections (UTI’s) 
Recurrent urinary tract infections (UTI’s) can be the first presentation of patients with 
necrotic infected bladder tumours. Therefore, it is always recommended to investigate 
recurrent UTI’s with cystoscopic examination to rule out associated bladder tumour. It is 
also believed that bladder stones, long term catheters, and ova of Schistosoma haematobium 
(bilharziasis) are all implicated in the development of squamous cell carcinoma of the 
bladder via the mechanism of chronic inflammation of bladder mucosa.   
6. Rare presentation symptoms and signs / symptoms and signs of advanced 
or complicated disease 
The natural history of bladder cancer can be classified as follows: 
- No further recurrence following initial presentation, diagnosis and treatment.  
- Local recurrence, which can occur on a single occasion or on multiple occasions. The 
recurrent tumours are usually of the same stage and grade as the primary tumour. 
Clinically patient may be asymptomatic or represent with haematuria or any other local 
symptoms.  
- Local Progresssion, which represent an increase in the local staging with time, the 
appearance of distant metastases and subsequent death. It is rare to encounter the 
symptoms and signs of advanced disease in the first presentation but patients with local 
recurrence and progression do represent with some of these symptoms and signs that 
are discussed below.  
6.1 Anaemia, Anorexia, weight loss and abdominal mass:  
Patients with large volume disease, muscle invasive tumours, or metastatic disease do 
sometimes present with these symptoms. The mass is properly assessed during 
bimanual examination under general anaesthesia and if it is immobile, this suggests 
that it is fixed to adjacent structures. Palpable masses that remain after local resection 
are likely to be extensive (non organ confined or T3 disease). The Tumour, Node, 
Metastasis(TNM) classification approved by the Union Internationale Contre le Cancer, 
which was updated in 2009 is shown in the table 3 (Sobin et al 2009): 
 
T Primary tumour.
TX primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Ta Noninvasive papillary carcinoma. 
Tis carcinoma in situ:`Flat tumour` 
T1 Tumour invades subepithelial connective tissue. 
T2 Tumour invades muscle
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     T2a Tumour invades superficial muscle (inner half)
     T2b Tumour invades Deep muscle (outer half) 
T3 Tumour invades perivesical tissue: 
     T3a Microscopically 
     T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: Prostate, Uterus, Vagina, Pelvic Wall, 
abdominal wall. 
      T4a Tumour invades prostate, uterus, or vagina. 
      T4b Tumour invades pelvic wall or abdominal wall.
N Lymph Nodes
Nx Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, Obturator, external 
iliac, or presacral). 
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric, Obturator, 
external iliac , or presacral). 
N3 Metastasis in a common iliac lymph node(s).
M Distant metastasis
Mx Distant metastasis cannot be assessed. 
M0 No distant metastasis. 
M1 Distant metastasis. 
Table 3. 2009 TNM classification of urinary bladder cancer 
6.2 Lower limb swelling and lymphedema:  
This is normally caused by occlusive pelvic lymphadenopathy or venous obstruction in 
the context of advanced disease. 
6.3 Hepatomegaly and supraclavicular lymphadenopathy:  
both are signs of metastatic disease.  
6.4 Pneumaturia:  
uncommon presentation of bladder cancer after enterovesical fistula formation. These 
type of fistulas are commoner with benign causes such as diverticular and crohn’s 
disease. (Dawam et al.,2004). Nevertheless, pneumaturia warrants further 
investigations with urine cytology and cystoscopy with bladder biopsy if any neoplastic 
lesions could be seen.  
6.5 Small bowel obstruction:  
uncommon and unusual presentation caused by large and advanced disease (Aigen et 
al.,1983).  
6.6 Renal failure:  
caused be blocked ureters due to extensive muscle invasive disease or unilateral 
blockage in case of malfunctioning or absent contralateral kidney. This could also be 
related to retroperitoneal metastasis.  
6.7 Painful cutaneous nodules and ulcerations:  
very unusual and rare site of metastasis (Fujita et al., 1994;Block et al.,2006).  
6.8 Urachal discharge (mucus or bloody):  
a very rare presentation of adenocarcinoma, which is a rare histological subtype of 
bladder cancer. The tumour could be in the urachus itself or at the dome of the urinary 
bladder. It could also present with mucosuria.  
6.9 Bony pain: a rare symptom that could be seen in cases of bony metastasis (Figure 3). 
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Fig. 3. An isotope bone scan of 38 year-old smoker female patient known to have G3pT2a 
bladder transitional cell carcinoma. She presented 2 years after radical radiation therapy 
with left sided hip pain. The bone scan shows wide spread metastasis ( Spine, Pelvis, left 
forearm, left tibia, right femur and tibia ).  
7. Clinical conditions that could predispose to delayed presentation 
7.1 Spina bifida patients 
Patients with spinal bifida and bladder cancer present at a young age with variable tumour 
histology and advanced stage and they also have poor survival. These patients have 
neuropathic bladder dysfunction in addition to the fact that bladder augmentation is a 
significant risk factor for developing bladder cancer. Presenting symptoms are often 
atypical. 
Although there has been suggestion of a role for annual serial bladder biopsies (Game et al., 
1999) but it is not clear yet if screening would be beneficial for earlier detection and 
improved outcome. However, bladder cancer should be a consideration in this patient 
population, even in young adults (Austin et al. 2007).            
7.2 Blind and colour blind patients 
In a study of 200 bladder cancer patients, we found that those who had colour blindness (21 
patients) did present with higher grade and stage disease compared to non colour blind 
population. The hypothesis is that these patients do not promptly notice the red colour of 
their urine at earlier stage, However, this is not proven. There is not sufficient evidence for 
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screening of colour blind patients for bladder cancer. However, it is advisable to keep these 
findings in mind when assessing colour blind patients as they may help in case finding and 
early diagnosis of bladder cancer in this group of patients (Katmawi-Sabbagh et al., 2009).  
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